Novo Holdings A/S
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 15, 2026), Novo Holdings A/S reported 22 stock positions worth $1.2 billion. Its top holding was Edgewise Therapeutics (EWTX) at 13.7% of the portfolio, followed by Brookfield (BN, 11.5%) and ASML Holding NV-NY Reg SHS (ASML, 10.2%). Compared with Q4 2025, it opened 1 new position, sold out of 3, added to 3 and reduced 7. The biggest buy was a new position in Xenon Pharmaceuticals (XENE) and the biggest sale an exit from Zenas Biopharma (ZBIO).
- Most Recent 13F
- Q2 2026
- Location
- HELLERUP, G7
- CIK
- 0001388325
- Portfolio Value
- $1.2B (Q1 2026)
- SEC Filing
- 0001388325-26-000026 ↗ filed May 15, 2026
Holdings Value
Holdings 22 stocks · $1.2B
| EWTX Edgewise Therapeutics Inc. | 13.65% | 5,350,000 | $168.5M | No change |
| BN Brookfield Corp. | 11.46% | 3,496,245 | $141.5M | No change |
| ASML ASML Holding NV-NY Reg SHS filed as ASML HLDG NV | 10.16% | 94,946 | $125.4M | Reduce -16.7% |
| MIRM Mirum Pharmaceuticals Inc. | 9.92% | 1,325,000 | $122.4M | Add +4.8% |
| MPLT Maplight Therapeutics Inc. | 6.07% | 3,686,622 | $74.9M | No change |
| CRM Salesforce Inc. | 5.95% | 393,187 | $73.4M | Add +19.1% |
| CRNX Crinetics Pharmaceuticals Inc. | 4.56% | 1,550,000 | $56.3M | Reduce -4.6% |
| ELVN Enliven Therapeutics Inc. | 4.07% | 1,280,000 | $50.2M | Reduce -13.5% |
| PCVX Vaxcyte Inc. | 4.05% | 860,000 | $50.0M | Reduce -6.1% |
| PHVS Pharvaris NV | 4.01% | 1,750,000 | $49.4M | No change |
| AVBP Arrivent Biopharma Inc. | 3.63% | 1,942,142 | $44.8M | No change |
| VRDN Viridian Therapeutics Inc. | 3.17% | 2,000,000 | $39.1M | Reduce -16.0% |
| CLDX Celldex Therapeutics Inc. | 3.08% | 1,200,000 | $38.1M | No change |
| APGE Apogee Therapeutics Inc. | 3.07% | 450,000 | $37.9M | Reduce -21.1% |
| BMRN Biomarin Pharmaceutical Inc. | 3.02% | 660,000 | $37.3M | No change |
| FDMT 4D Molecular Therapeutics Inc. | 2.75% | 3,650,737 | $34.0M | No change |
| BABA Alibaba Group Holding-SP ADR | 2.62% | 257,327 | $32.3M | No change |
| XENE Xenon Pharmaceuticals Inc. | 2.29% | 485,438 | $28.2M | New |
| BBOT Bridgebio Oncology Therapeut | 1.59% | 2,185,923 | $19.6M | Add +11.4% |
| VALN Valneva SE - ADR | 0.54% | 1,057,421 | $6.6M | Reduce -54.1% |
| LNZA Lanzatech Global Inc. | 0.21% | 158,148 | $2.5M | No change |
| MQ Marqeta Inc. | 0.15% | 441,558 | $1.8M | No change |
Portfolio Sells Q4 2025 → Q1 2026
| ZBIO Zenas Biopharma Inc. | Sold out | 0.00% | −4.09 |
| INSM Insmed Inc. | Sold out | 0.00% | −2.70 |
| VRDN Viridian Therapeutics Inc. | Reduce -16.0% | 3.17% | −2.58 |
| CRNX Crinetics Pharmaceuticals Inc. | Reduce -4.6% | 4.56% | −1.31 |
| VALN Valneva SE - ADR | Reduce -54.1% | 0.54% | −1.04 |
| APGE Apogee Therapeutics Inc. | Reduce -21.1% | 3.07% | −0.27 |
| IOBTQ Io Biotech Inc. | Sold out | 0.00% | −0.12 |
| ASML ASML Holding NV-NY Reg SHS | Reduce -16.7% | 10.16% | +0.69 |
| PCVX Vaxcyte Inc. | Reduce -6.1% | 4.05% | +0.77 |
| ELVN Enliven Therapeutics Inc. | Reduce -13.5% | 4.07% | +2.30 |
Portfolio Buys Q4 2025 → Q1 2026
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 25 | $1.7B | EWTX, ASML, COAG, BN, MPLT |
| Q1 2026 | 22 | $1.2B | EWTX, BN, ASML, MIRM, MPLT |
| Q4 2025 | 24 | $1.3B | BN, EWTX, ASML, MIRM, CRM |
| Q3 2025 | 27 | $1.6B | VTI, BN, ASML, MIRM, EWTX |
| Q2 2025 | 29 | $1.4B | VTI, BN, ASML, CRM, MIRM |
| Q1 2025 | 31 | $1.3B | VTI, BN, EWTX, ASML, CRM |
| Q4 2024 | 34 | $1.7B | VTI, BN, TEM, EWTX, ASML |
| Q3 2024 | 37 | $2.0B | VTI, TEM, BN, EWTX, CORT |
| Q2 2024Amended | 38 | $1.9B | VTI, BN, TEM, ASML, CRM |
| Q1 2024 | 35 | $1.4B | ASML, BN, CRM, EPC, CORT |